Serial Number | 90441024 |
Word Mark | BIOMEA FUSION |
Filing Date | Thursday, December 31, 2020 |
Status | 733 - FOURTH EXTENSION - GRANTED |
Status Date | Tuesday, August 13, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, March 8, 2022 |
Goods and Services | Chemotherapeutics; Adjuvants for medical purposes; Anti-cancer preparations; Anti-sarcoma preparations; Cellular function activating agents for medical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for cancer and metabolic diseases; Cytostatics for pharmaceutical purposes; Diagnostic preparations for medical purposes; Medical preparations for the treatment of cancer and metabolic diseases; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for cancer and metabolic diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the prevention of cancer and metabolic diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of cancer and metabolic diseases; Pharmaceutical preparations for the treatment and prevention of cancer and metabolic diseases; Pharmaceutical preparations for cancer and metabolic diseases; Pharmaceutical preparations, namely, elixirs for the treatment of cancer and metabolic diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer and metabolic diseases; Tumor suppressing agents; Medicinal infusions for treating cancer and metabolic diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents |
Goods and Services | Biotechnology research; Development of new technology for others in the field of cancer and metabolic diseases; Development of pharmaceutical preparations and medicines; Medical and scientific research in the field of cancer treatment and diagnosis; Pharmaceutical drug development services; Pharmaceutical products development; Pharmaceutical research and development; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer and metabolic diseases; Testing of pharmaceuticals; Medical research services; Pharmaceutical research services; Research and development of vaccines and medicines |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, March 30, 2021 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, March 30, 2021 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | Biomea Fusion, Inc. |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 03 - Corporation |
Address | Redwood City, CA 94063 |
Party Name | Biomea Fusion, Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Redwood City, CA 94063 |
Event Date | Event Description |
Tuesday, March 30, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Monday, January 4, 2021 | NEW APPLICATION ENTERED |
Friday, June 11, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Friday, June 11, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Friday, June 11, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Wednesday, July 7, 2021 | ASSIGNED TO EXAMINER |
Thursday, July 15, 2021 | NON-FINAL ACTION WRITTEN |
Thursday, July 15, 2021 | NON-FINAL ACTION E-MAILED |
Thursday, July 15, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Tuesday, January 18, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Tuesday, January 18, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Wednesday, January 19, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Tuesday, February 1, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, February 16, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, March 8, 2022 | PUBLISHED FOR OPPOSITION |
Tuesday, March 8, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Thursday, April 7, 2022 | EXTENSION OF TIME TO OPPOSE RECEIVED |
Friday, June 10, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
Friday, June 10, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Friday, June 10, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
Friday, June 10, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Friday, June 10, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Sunday, July 17, 2022 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
Tuesday, August 30, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Thursday, December 15, 2022 | SOU TEAS EXTENSION RECEIVED |
Thursday, December 15, 2022 | SOU EXTENSION 1 FILED |
Thursday, December 15, 2022 | SOU EXTENSION 1 GRANTED |
Saturday, December 17, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, August 11, 2023 | SOU TEAS EXTENSION RECEIVED |
Friday, August 11, 2023 | TEAS REQUEST TO DIVIDE RECEIVED |
Friday, August 11, 2023 | DIVISIONAL REQUEST RECEIVED |
Friday, August 11, 2023 | SOU EXTENSION 2 FILED |
Monday, August 28, 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Tuesday, August 29, 2023 | DIVISIONAL PROCESSING COMPLETE |
Tuesday, August 29, 2023 | SOU EXTENSION 2 GRANTED |
Wednesday, August 30, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Friday, September 15, 2023 | CORRECTED NOA E-MAILED |
Thursday, February 8, 2024 | SOU TEAS EXTENSION RECEIVED |
Thursday, February 8, 2024 | SOU EXTENSION 3 GRANTED |
Thursday, February 8, 2024 | SOU EXTENSION 3 FILED |
Tuesday, August 13, 2024 | SOU TEAS EXTENSION RECEIVED |
Tuesday, August 13, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Tuesday, August 13, 2024 | SOU EXTENSION 4 FILED |
Tuesday, August 13, 2024 | SOU EXTENSION 4 GRANTED |
Friday, February 9, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |